Innovation | Novartis

Media Release
Oct 29, 2024
Novartis Scemblix® FDA approved in newly diagnosed CML, offering superior efficacy, and favorable safety and tolerability profile
Story
Oct 29, 2024
My Journey to Novartis: Finding my Purpose and Passion
Media Release
Oct 24, 2024
Novartis ribociclib (Kisqali®) recognized as Category 1 preferred breast cancer adjuvant treatment by NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®)
Media Release
Sep 18, 2024
New Novartis data in relapsing MS reinforce benefits of Kesimpta® for first-line and switch patients
Media Release
Sep 17, 2024
FDA approves Novartis Kisqali® to reduce risk of recurrence in people with HR+/HER2- early breast cancer
Story
Aug 02, 2024
Is Diversity, Equity and Inclusion (DEI) really that important?
Media Release
Jul 29, 2024
Novartis Scemblix® granted FDA Priority Review for the treatment of adults with newly diagnosed CML
Media Release
Jul 18, 2024
Novartis erzielt im zweiten Quartal weiterhin kräftige Umsatzsteigerungen und erhöht die Kerngewinnmarge; Gewinnprognose für das Geschäftsjahr 2024 angehoben
Media Release
Jul 18, 2024
Novartis a poursuivi au T2 la forte croissance de son chiffre d’affaires et l’expansion de sa marge core; hausse des prévisions de son résultat opérationnel core pour 2024
Media Release
Jul 18, 2024
Novartis continues to deliver strong sales growth and core margin expansion in Q2; raises FY 2024 bottom-line guidance
Media Release
May 31, 2024
Novartis Phase III data confirm sustained efficacy and long-term safety of oral remibrutinib in chronic spontaneous urticaria
Media Release
May 25, 2024
Novartis atrasentan Phase III data show clinically meaningful proteinuria reduction further advancing company's IgA nephropathy (IgAN) portfolio